RESEARCH MONOGRAPH · KDC-MN-047

Rivastigmine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

77/100

Dual AChE/BuChE inhibitor with the most interesting pharmacology of the approved cholinesterase class

Rivastigmine is the cholinesterase inhibitor that does something the others dont, namely hit butyrylcholinesterase at clinically relevant concentrations alongside AChE. Whether that matters is a genuine open question in the field, but the pharmacology is interesting enough to be worth understanding.

The mechanism splits between the standard AChE inhibition and the BuChE arm. BuChE is interesting because its expression pattern in human brain changes with disease, with relative BuChE activity climbing as AChE drops in advanced Alzheimer's. The Giacobini work argued that dual inhibition is therefore more relevant in late-stage disease, which is a coherent story even if the clinical evidence for it is mixed.

The pharmacology is also unusual in that rivastigmine is a pseudo-irreversible carbamate inhibitor rather than a reversible competitive one. So the duration of cholinesterase inhibition outlasts the systemic half-life by a lot, which has real implications for dosing schedules and is part of why the patch formulation makes sense (avoids the gut-related GI side effects of oral dosing).

What we like: the dual mechanism is genuinely distinct from donepezil and galantamine, the carbamate kinetics are pharmacologically interesting in their own right, and the human data in both Alzheimer's and Parkinson's-related dementia is solid. Novartis ran the trials well.

What we dont like: the GI side effect profile in oral dosing is significantly worse than donepezil, the dose-titration window is annoying, and whether BuChE inhibition actually adds clinical value is still genuinely uncertain. The patch fixes a lot of the tolerability problems but limits research utility.

For research, rivastigmine is the tool you reach for if you specifically want dual cholinesterase inhibition or want to study carbamate-mediated pseudo-irreversible kinetics. For straight AChE work, donepezil is cleaner.

Sourcing is reasonable. Generic for years, pharmacopoeia-grade material is widely available, multiple reputable suppliers, HPLC straightforward. The freebase versus tartrate salt distinction matters for solubility work.

One of the more underrated tools on the cholinergic shelf. Not the right answer for every question, but for the BuChE-specific or carbamate-kinetic experiments, this is the molecule.

Evidence: 88
Mechanism: 82
Reliability: 82
Safety: 65
Sourcing: 85
Value: 75
Signal: 65
Staying power: 75

Plain-language summary Intrigue 68 / 100

Rivastigmine, sold as Exelon, is an acetylcholinesterase and butyrylcholinesterase inhibitor approved for Alzheimer and Parkinson disease dementia. Available as oral capsule and transdermal patch. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Acetylcholinesterase + butyrylcholinesterase inhibitor

A pseudo-irreversible carbamate dual cholinesterase inhibitor approved for Alzheimer disease and Parkinson disease dementia, available as oral and transdermal formulations.

Abstract

Rivastigmine (Exelon; CAS 123441-03-2; molecular formula C14H22N2O2; molecular weight 250.34) is a pseudo-irreversible carbamate cholinesterase inhibitor approved by the FDA in 2000 for mild-to-moderate Alzheimer disease and subsequently expanded to Parkinson disease dementia. The compound is distinctive among the marketed AChE inhibitors in showing dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE); BChE may play a more prominent role in advanced Alzheimer disease as AChE expression declines, providing a theoretical advantage for rivastigmine in later disease stages. The pseudo-irreversible mechanism involves carbamoylation of the AChE serine residue, with slow regeneration over hours. Pharmacokinetics: short plasma half-life of the parent compound (1 to 2 hours) but the carbamoylation produces extended pharmacological effect (8 to 10 hours functional duration). Available as oral capsules and a transdermal patch (Exelon Patch); the patch produces smoother plasma exposure with reduced gastrointestinal adverse events. Reported research dose ranges in the literature span 6 to 12 mg oral or 4.6 to 13.3 mg/24 hr transdermal.

Mechanism of action

Pseudo-irreversible carbamate inhibitor of both AChE and BChE; carbamoylation produces extended functional effect.

Reported research dose ranges

Reported research dose ranges in the literature span 6 to 12 mg oral or 4.6 to 13.3 mg/24 hr transdermal.

References

Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998.
Birks J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2015.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-047

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Rivastigmine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs